#Obesity medicine

Chronic weight management as a clinical specialty.

An Iranian 68-week model found semaglutide cost-effective at its threshold, while tirzepatide offered more benefit at a higher estimated cost.

A matched cohort linked GLP-1 receptor agonist use with less one-year atrial fibrillation in non-diabetic adults with obesity and CKD.

A mouse and cell study found tirzepatide reduced selected inflammatory responses after a Western diet. It was not a clinical outcomes trial.

A 2026 GLP-1 hair loss review links shedding mainly to weight change, but the narrative evidence cannot prove direct drug causation.

A 2026 meta-analysis found GLP-1 therapy reduced intake by about 271 kcal at one test lunch, with real-world diet effects still uncertain.

A 70-person observational study linked four months of oral semaglutide care with lower weight, mostly through reduced fat mass.

A 2026 pediatric obesity drug review links adolescent semaglutide evidence with adult retatrutide research while leaving long-term safety open.

A 2026 review finds short-term benefits from adolescent GLP-1 therapy but major gaps around growth, puberty, cognition and lifelong effects.

A non-randomized Japanese cohort reported similar six-month weight loss with 2.5 mg and 5 mg tirzepatide, without proving dose equivalence.

A 2026 meta-analysis links tirzepatide to lower cardiorenal biomarkers, while functional and kidney findings remain based on single trials.

A mouse study tested sulforaphene-loaded α-lactalbumin nanomicelles against semaglutide, but it provides no human efficacy or safety evidence.

Australian sales and PBS data show rapid GLP-1 medicine growth, with nearly half of estimated use accessed privately in the final study year.